Literature DB >> 26362367

The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.

Thomas B Dodson1.   

Abstract

This article provides the best current frequency estimate of medication-related osteonecrosis of the jaws (MRONJ), and identifies factors associated with the risk of developing osteonecrosis of the jaw (ONJ) among patients exposed to relevant medications (ie, antiresorptive or antiangiogenic agents). MRONJ is a rare but serious complication of cancer treatment or osteoporosis management. This review confirms that antiresorptive medications such as oral or intravenous bisphosphonates and denosumab are the most common risk factors for developing ONJ. The risk of MRONJ is greater in patients with cancer than in those receiving antiresorptive treatments for osteoporosis by a factor of 10.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antiangiogenic agents; Antiresorptive medications; Frequency; Medication-related osteonecrosis of the jaws; Oral bisphosphonates; Risk factors; Zolendronate

Mesh：

Substances：

Year:  2015        PMID： 26362367     DOI： 10.1016/j.coms.2015.06.003

Source DB:  PubMed          Journal:  Oral Maxillofac Surg Clin North Am        ISSN： 1042-3699            Impact factor:   2.802


  25 in total

Review 1.  Underprescription of medications in older adults: causes, consequences and solutions-a narrative review.

Authors:  F Lombardi; L Paoletti; B Carrieri; G Dell'Aquila; M Fedecostante; M Di Muzio; A Corsonello; F Lattanzio; A Cherubini
Journal:  Eur Geriatr Med       Date:  2021-03-11       Impact factor: 1.710

2.  Radiographic predictors of bone exposure in patients with stage 0 medication-related osteonecrosis of the jaws.

Authors:  Akrivoula Soundia; Danny Hadaya; Sanjay M Mallya; Tara L Aghaloo; Sotirios Tetradis
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2018-08-29

3.  Role of osteoclasts in oral homeostasis and jawbone diseases.

Authors:  Maiko Omi; Yuji Mishina
Journal:  Oral Sci Int       Date:  2020-07-21

4.  Uncommon presentation of medication-related osteonecrosis of the mandible in a patient with metastatic prostate cancer.

Authors:  Meera Thavarajah; Rahul Jayaram
Journal:  BMJ Case Rep       Date:  2019-02-26

5.  Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report.

Authors:  Xerxes Pundole; Amy Little Jones; Michael T Tetzlaff; Michelle D Williams; William A Murphy; Adegbenga Otun; Ryan P Goepfert; Michael A Davies
Journal:  Immunotherapy       Date:  2020-09-09       Impact factor: 4.196

6.  Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients.

Authors:  Adepitan A Owosho; Ariel Blanchard; Lauren Levi; Arvin Kadempour; Haley Rosenberg; SaeHee K Yom; Azeez Farooki; Monica Fornier; Joseph M Huryn; Cherry L Estilo
Journal:  J Craniomaxillofac Surg       Date:  2015-12-20       Impact factor: 2.078

Review 7.  Diabetes, bone and glucose-lowering agents: clinical outcomes.

Authors:  Ann V Schwartz
Journal:  Diabetologia       Date:  2017-04-27       Impact factor: 10.122

8.  Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series.

Authors:  Adepitan A Owosho; Cherry L Estilo; Joseph M Huryn; SaeHee K Yom
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2016-07-13

9.  Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users.

Authors:  P A Eiken; D Prieto-Alhambra; R Eastell; B Abrahamsen
Journal:  Osteoporos Int       Date:  2017-06-29       Impact factor: 4.507

Review 10.  Interventions for managing medication-related osteonecrosis of the jaw.

Authors:  Natalie H Beth-Tasdogan; Benjamin Mayer; Heba Hussein; Oliver Zolk
Journal:  Cochrane Database Syst Rev       Date:  2017-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.